Lunch 'n Learn: Exploring FcRn blockade in gMG: A case-based approach

Wednesday, May 22, 2024

12:15 PM – 1:45 PM EST

Location:MM: Confederation 5 & 6

Audience:

Adult Neurologists, Residents, Fellows, Nurses with interest in MG

Learning Level:

Intermediate (Practicing Physician)

Learning Format:

Audience response system, Case studies, Forum/panels, Question and answer sessions

CanMEDs Roles:

Medical Expert, Scholar, Communicator, Collaborator, Leader, Professional

Faculty(s)

Please join us for a case-based, interactive session as our expert faculty discusses evolving data on the role of neonatal Fc receptor (FcRn) inhibition in generalized myasthenia gravis (gMG). The faculty will present recent clinical evidence for efgartigimod alfa in the treatment of patients with AChR antibody-positive (AChRAb+) gMG. They will review key clinical data that help inform decisions around therapeutic options and discuss real-world patient cases and practical considerations for improving patient outcomes. Results of real-time audience polling will direct the flow and content of the session.

This program was developed by the CNSF and Argenx and was planned to achieve scientific integrity, objectivity and balance. It is an unaccredited learning activity and not eligible for MOC credits.

Learning Objectives:

Explain the rationale for targeting FcRn in gMG
Describe clinical, real-world evidence and place in therapy for efgartigimod
Identify treatment options to improve care for patients with gMG

Presentations:

12:15 PM – 12:20 PM EST

Welcome, introductions, and learning objectives
Faculty: Vera Bril
12:20 PM – 12:45 PM EST

Review of clinical evidence for efgartigimod in the treatment of gMG
Faculty: Vera Bril
Faculty: Oliver Blanchard
12:45 PM – 1:35 PM EST

Interactive session: Real-world gMG cases
Faculty: Nicholas Silvestri
1:35 PM – 1:45 PM EST

Panel discussion
Faculty: Vera Bril
Faculty: Oliver Blanchard
Faculty: Nicholas Silvestri